Brief: Moberg Pharma Unit Announces Issue Of European Patent Related To BupiZenge
Jan 7 (Reuters) - Moberg Pharma AB (publ) MBPH.ST :
* ONCOZENGE ANNOUNCES ISSUE OF EUROPEAN PATENT RELATED TO
BUPIZENGE ®
* PATENT IS EXPECTED TO BE IN EFFECT UNTIL 2032.
Source text for Eikon: ID:nWkr2vL4PG
Further company coverage: MBPH.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Moberg Pharma AB (publ)
See all newsSweden's Moberg Pharma Q2 loss narrows as revenue rises
Brief: Moberg Pharma Q2 EBITDA SEK -4.3 Million
Brief: Moberg Pharma Names Vaidrius Navikas Chief Medical Officer
Brief: Moberg Pharma And Karo Healthcare Expand Collaboration
Moberg Pharma Q1 revenue rises, losses narrow on Nordic market share gains